PN-477sc
Obesity & Associated Co-Morbidities
IND-EnablingPhase 1 initiation Mid 2026
Key Facts
Indication
Obesity & Associated Co-Morbidities
Phase
IND-Enabling
Status
Phase 1 initiation Mid 2026
Company
About Protagonist Therapeutics
Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.
View full company profileOther Obesity & Associated Co-Morbidities Drugs
| Drug | Company | Phase |
|---|---|---|
| PN-477oral | Protagonist Therapeutics | IND-Enabling |